Thermo Fisher (NYSE: TMO) is acquiring Mesa Biotech, developer of a PCR-based rapid point-of-care (PoC) testing platform for infectious diseases. Mesa Biotech’s Accula System has received Emergency Use Authorization (EUA) for SARS-CoV-2 in vitro diagnostic testing, providing results within 30 minutes, with greater precision than other rapid tests. The Accula System also can screen for Influenza A and B, respiratory syncytial virus (RSV) and Strep A. Deal terms – $450m upfront on sales of $45m (10x) plus up to another $100m in milestones.
Keywords: Healthcare Investment Banking, Healthcare M&A, Healthcare Mergers, Diagnostics, Testing